Vaccinex receives Nasdaq delisting notice for failing equity standard; will appeal

VACCINEX, INC.

Company failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement for continued listing.
Nasdaq granted extension until Sept 30, 2024, to regain compliance; company did not comply.
On Oct 7, 2024, Nasdaq determined to delist unless company timely appeals to a Hearings Panel.
Company intends to appeal, which automatically stays suspension and delisting pending Panel decision.
No assurance that Hearings Panel will grant continued listing or that compliance will be achieved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.